Grace Therapeutics (GRCE) Liabilities and Shareholders Equity (2017 - 2026)

Grace Therapeutics has disclosed Liabilities and Shareholders Equity across 10 years of filings, most recently posting $50.1 million for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity fell 28.27% year-over-year to $50.1 million; the TTM figure through Jun 2026 stood at $251.8 million (down 6.18% YoY), while the FY2026 annual figure was $66.7 million, down 7.42% from the prior year.
• Liabilities and Shareholders Equity came in at $50.1 million for Q2 2026 at Grace Therapeutics, down from $66.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $128.6 million in Q1 2022 to a low of $50.1 million in Q2 2026.
• Average Liabilities and Shareholders Equity over 5 years is $81.2 million, with a median of $72.5 million recorded in 2023.
• Year-over-year, Liabilities and Shareholders Equity soared 106.66% in 2022 and tumbled 41.54% in 2023.
• Over 5 years, Liabilities and Shareholders Equity stood at $116.8 million in 2022, then slumped by 34.77% to $76.2 million in 2023, then slipped by 19.64% to $61.2 million in 2024, then rose by 11.86% to $68.5 million in 2025, then declined by 26.89% to $50.1 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $50.1 million in Q2 2026, $66.7 million in Q1 2026, and $68.5 million in Q4 2025.